Isolated Limb Infusion for Limb-Threatening Sarcomas
Annals of Surgical Oncology · 2024
DOI: 10.1245/s10434-024-16159-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Surgical Oncology, 2024. Verfasst von Shaliz Aflatooni und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL, USA. Hauptthemen laut MEDLINE: Sarcoma, Dactinomycin, Melphalan, Chemotherapy, Cancer, Regional Perfusion. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Isolated limb infusion (ILI) treats unresectable extremity malignancies with high-dose regional chemotherapy limited to the limb. This study assessed long-term outcomes after ILI for limb-threatening sarcomas. METHODS: A retrospective review analyzed patients with an extremity sarcoma who underwent ILI with melphalan and dactinomycin from 2008 to 2023 at a single institution. RESULTS: The study identified 61 patients (52.5% female; median age, 73 years; range, 20-94 years). Of these patients, 68.9% had lower-extremity disease. The median follow-up period was 6.9 years. The overall response rate was 48.3% (complete response [CR], 21.7%; partial response [PR], 26.7%), and the disease control rate (DCR: CR + PR + stable disease [SD]) was 65%. The median progression-free survival (PFS) for the patients with CR/PR/SD/progressive disease (PD) was respectively 16.8/9.6/4.8/2.4 months (P < 0.0001). The responders (CR + PR) had significantly longer PFS than the non-responders (SD + PD) (hazard ratio [HR], 6.3; 95% confidence interval [CI], 3.1-12.9; P < 0.001). The median in-field PFS times for CR/PR/SD/PD were respectively 16.8/12/4.8/2.4 months (P < 0.001). The responders had a significantly longer risk of in-field PFS than the non-responders (HR, 5.9; 95% CI 2.9-12.0; P < 0.001). The median distant relapse PFS for CR/PR/SD/PD was not reached (NR)/NR/44.4/40.8 months (P = 0.02). The responders had a significantly longer distant relapse PFS than the non-responders (HR, 2.7; range, 1.1-6.8; P = 0.04). The median overall survival (OS) was 8.6 years for the responders and 4.1 years for the non-responders (P = 0.02). The disease-specific survival (DSS) rates were 87% at 1 year, 71% at 3 years, and 64% at 5 years. The median DSS was not reached for the responders and was 4.1 years for the non-responders (P = 0.003). The limb salvage rates at 6 months were 85% at 1 year, 80% at 3 years, and 70% at 5 years. The patients with PD had a higher risk of requiring amputation than the patients with CR + PR + SD (HR, 3.0; 95% CI 1.0-8.7; P = 0.04). CONCLUSIONS: The 5-year limb salvage rates after ILI are notably high, reaching 70%. After ILI, the responders had significantly better in-field and distant relapse PFS, OS, and DSS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
- Cutaneous Oncology Department, Moffitt Cancer Center, Tampa, FL, USA.
- Department of General Surgery, University of Massachusetts Chan Medical School, Boston, MA, USA.
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
- Sarcoma Department, Moffitt Cancer Center, Tampa, FL, USA.
- Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Zitieren
APA
Aflatooni, S., Dugan, M. M., Boby, A., Ghali, H., DePalo, D. K., Naqvi, S. M. H., Mullinax, J. E., & Zager, J. S. (2024). Isolated Limb Infusion for Limb-Threatening Sarcomas. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-024-16159-y
Vancouver
Aflatooni S, Dugan MM, Boby A, Ghali H, DePalo DK, Naqvi SMH, et al. Isolated Limb Infusion for Limb-Threatening Sarcomas. Annals of Surgical Oncology. 2024. doi:10.1245/s10434-024-16159-y
BibTeX
@article{Aflatooni2024,
author = {Aflatooni, Shaliz and Dugan, Michelle M and Boby, Aleena and Ghali, Helana and DePalo, Danielle K and Naqvi, Syeda Mahrukh Hussnain and Mullinax, John E and Zager, Jonathan S},
title = {Isolated Limb Infusion for Limb-Threatening Sarcomas},
journal = {Annals of Surgical Oncology},
year = {2024},
doi = {10.1245/s10434-024-16159-y}
}
EUVIMED